Abstract
Nonsmall cell lung cancer accounts for approximately 80% of all lung cancers, and approximately 75% of cases are diagnosed in the middle and late stages of disease. Unfortunately, limited treatment does not improve the prognosis of advanced disease. Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) represent a new treatment paradigm for nonsmall cell lung cancer. Nevertheless, the immune-related adverse events (irAEs) associated with PD-1 and PD-L1 inhibitors are unique, and early recognition and treatment of these events are essential. A systematic literature search will be performed using the EMBASE, MEDLINE, and Cochrane databases to identify relevant articles published in any language. Randomized clinical trials, case series, and case reports of PD-1 and PD-L1 inhibitors in the treatment of nonsmall cell lung cancer will be included. All meta-analyses will be performed using RevMan software. The quality of the studies will be evaluated using the guidelines listed in the Cochrane Handbook. If the necessary data are available, then subgroup analyses will be performed for high-, median-, and low-dose cohorts. The Preferred Reporting Items for Systematic Reviews and Met...Continue Reading
References
Feb 22, 2002·Cancer·Constance G BaconIchiro Kawachi
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lorna ButlerAndrea Bezjak
Sep 11, 2004·FEBS Letters·Kelly-Ann SheppardDivya Chaudhary
May 30, 2006·Advances in Immunology·Charles G DrakeDrew M Pardoll
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Mar 5, 2008·Mayo Clinic Proceedings·Taimur SherAlex A Adjei
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Mar 11, 2015·Therapeutic Advances in Medical Oncology·Raghav SundarRoss A Soo
Mar 22, 2015·The Lancet Oncology·Jeffrey S WeberJames Larkin
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 19, 2015·Cell Death & Disease·Y JiangB Zhu
Jun 28, 2015·The Lancet Oncology·Antoni RibasAdil Daud
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Oct 27, 2015·Pharmacotherapy·Ninh M La-BeckDevin B Lowe
Dec 30, 2015·Lancet·Roy S HerbstEdward B Garon
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Feb 19, 2016·OncoTargets and Therapy·Wang JingHui Zhu
Mar 14, 2016·Lancet·Louis FehrenbacherUNKNOWN POPLAR Study Group
Mar 7, 2017·Therapeutics and Clinical Risk Management·Alexander D LeNinh M La-Beck
Citations
Jun 12, 2019·BMC Cancer·Xiaoying SunXin Li
Oct 5, 2018·BMC Cancer·Motoko TachiharaSoichiro Yokota
Jul 27, 2018·Scientific Reports·Jian XuNini Wang